BioAge Labs (NASDAQ:BIOA) Rating Lowered to Sell at Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

Several other brokerages also recently issued reports on BIOA. Citigroup upped their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $15.00.

BioAge Labs Stock Up 7.3%

Shares of BIOA stock opened at $19.60 on Monday. BioAge Labs has a twelve month low of $2.88 and a twelve month high of $24.00. The company has a market cap of $702.66 million, a P/E ratio of -12.89 and a beta of 1.38. The business has a fifty day simple moving average of $13.85 and a 200 day simple moving average of $8.43.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million during the quarter.

Insiders Place Their Bets

In related news, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total transaction of $531,900.00. Following the transaction, the chief financial officer directly owned 22,408 shares in the company, valued at approximately $441,437.60. The trade was a 54.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Paul D. Rubin sold 68,897 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $10.19, for a total transaction of $702,060.43. The disclosure for this sale is available in the SEC filing. Insiders have sold 347,004 shares of company stock valued at $5,673,859 in the last three months. 20.82% of the stock is currently owned by insiders.

Institutional Trading of BioAge Labs

A number of hedge funds have recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey bought a new position in BioAge Labs in the 2nd quarter valued at $27,000. Russell Investments Group Ltd. purchased a new stake in BioAge Labs during the third quarter worth about $27,000. CWM LLC increased its holdings in BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after acquiring an additional 5,976 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new position in BioAge Labs in the second quarter valued at about $57,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.